Globe ImageIDS News Text

 

Ongoing Trials Reported to IDIG

 

In Type 1 Diabetes at Diagnosis

 

Trial Name: Autoantigen Vaccination in Human Type 1 Newly Diagnosed Diabetes Mellitus
Agent: Human insulin B-chain in IFA
Investigator:

Tihamer Orban M.D.

Contact: or

 

Trial Name: IMDIAB 8
Agent: Continuous Subcutaneous Insulin Therapy (pump)
Vs. Intensive Insulin Therapy
Investigator:

Dr. Paolo Pozzilli

Contact:

 

Trial Name: IMDIAB 9
Agent: Nicotinamide and Vitamin E vs. Vitamin E
Investigator:

Dr. Paolo Pozzilli

Contact:

 

Trial Name: Immunotherapy Trial in New Onset Type 1 Diabetes
Agent: Beta Mycophenolate mofetil alone (up to 250 mg 4 tabs BID PO)
BetaMycophenolate mofetil placebo (up to 250 mg 4 tabs BID PO)
Beta Mycophenolate mofetil (up to 250 mg 4 tabs BID PO) and Daclizumab (1mg/kg IV infusion) together.
Investigator: Dr. Peter A. Gottlieb
Contact: , or

 

Trial Name: Immunintervention with 1,25-Dihydroxy-Vitamine D3 in subjects with recently diagnosed type 1 diabetes mellitus
Agent: 1,25-Dihydroxy-Vitamine D3, 0.25 µg per day
Investigator: Dr Anette Ziegler
Contact:

 

Trial Name: Ingested Interferon Alpha: Preservation of Residual Beta Cell Function in Newly Diagnosed Diabetes Mellitus
Agent: Ingested IFN-alpha2a
Investigator:

Dr Staley A. Brod

Contact:

 

Trial Name: NBI 6024-003
Agent: Incremental single doses of NBI 6024 or placebo administered subcutaneously.
Investigator: Dr. Peter A. Gottlieb
Contact: or

 

Trial Name: Phase II trial of hOKT3 gamma 1(Ala-Ala) for treatment of new onset Type 1 diabetes mellitus
Agent: hOKT3 gamma 1(Ala-Ala)
Investigator:

Dr. Kevan Herold, MD

Contact:

 

Trial Name:
Agent: Daclizumab Therapy
Investigator:

Henry Rodriguez, M.D.

Contact: or

 

In Pre-Type 1 Diabetes

 

Trial Name: Diabetes Prevention Trial Type 1 diabetes
Agent: Oral Insulin
Investigator:

Dr Jay Skyler

Contact: or